rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Zoetis Inc.

ZTS · NYSE

Health CarePharmaceuticalsNot moving yet

ZTS stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 7.7% below that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
31% -7 in 4 wk
Insider buys, 12 months
$1.8M
Insider sales, 12 months
$5.1M
Officials’ trades on record
154

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
26%36%46%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$4.8M$0$1.5MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

154 disclosed lines: House 107, Senate 28, executive 19; 34 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k18 Sep 2026filed 12 Oct 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$50k–$100k27 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k24 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k23 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$500k–$1M20 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k17 Jul 2026filed 22 Sep 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k17 Jul 2026filed 4 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$250k–$500k8 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k8 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$50k–$100k24 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k23 Jun 2026filed 22 Aug 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k16 Jun 2026filed 2 Jul 2026

Insiders

Buy orders, 12 months3
Sale orders, 12 months1
Buyers · sellers3 · 1
WhoDidSharesTraded
Paul BisaroDirectorbought2,000at $75.8813 May 2026filed 13 May 2026
Frank A. DamelioDirectorbought6,650at $75.3913 May 2026filed 13 May 2026
Michael B. McCallisterDirectorbought3,000at $77.7611 May 2026filed 12 May 2026
Kristin C. PeckChief Executive Officersold9,200at $126.4617 Feb 2026filed 17 Feb 2026
Kristin C. PeckChief Executive Officersold10,800at $127.5517 Feb 2026filed 17 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Abhay U. Nayak Company insiderExecutive Vice President · last 9 Oct 20260 · 0
Astorga Jeannette Ferran Company insiderExecutive Vice President · last 9 Oct 20260 · 0
Julie Fuller Company insiderExecutive Vice President · last 9 Oct 20260 · 0
Keith Sarbaugh Company insiderExecutive Vice President · last 9 Oct 20260 · 0
Kevin Esch Company insiderExecutive Vice President · last 9 Oct 20260 · 0
Kristin C. Peck Company insiderChief Executive Officer · last 9 Oct 20260 · 26
Rimma Driscoll Company insiderExecutive Vice President · last 9 Oct 20260 · 0
Roxanne Lagano Company insiderExecutive Vice President · last 9 Oct 20261 · 42
Gilbert Ray Cisneros, Jr. HouseCA31 · last 18 Sep 20265 · 4
Mark Stetter Company insiderDirector · last 17 Sep 20260 · 0
James Saccaro Company insiderEVP, CFO & COO · last 31 Aug 20260 · 0
Frank A. Damelio Company insiderDirector · last 7 Aug 20262 · 0

Same industry

ABBV AbbVieLeading+20%
VTRS ViatrisLeading+16%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202571.8%
Free cash flow marginFY 2025 · to 31 Dec 202524.1%
Cash conversionFY 2025 · to 31 Dec 2025109%
Debt to equityFY 2025 · to 31 Dec 20252.71×
Share count trendFY 2025 · to 6 Feb 2026-0.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.3B
Free cash flowFY 2025 · to 31 Dec 2025$2.3B

Analyst forecasts

No analyst forecasts yet.